Amgen Inc., et al., Petitioners v. Sanofi, et al.

  1. July 15, 2022

    Patent Cases To Watch In The Second Half Of 2022

    The U.S. Supreme Court will consider several appeals from drugmakers seeking clarity on what constitutes an adequate written description for a patent, and a high-profile dispute over so-called "skinny labels" for generic drugs. Here are the cases to keep an eye on for the rest of the year.

  2. April 18, 2022

    Justices Want SG's Take On Enablement In Antibody IP Fight

    The U.S. Supreme Court asked the solicitor general Monday to weigh in on Amgen's bid to undo a Federal Circuit decision tossing its jury win against Sanofi and Regeneron Pharmaceuticals Inc. after finding two antibody patents on its cholesterol medication Repatha aren't enabled.

  3. March 14, 2022

    Fed. Circ. Was Right To Deny Amgen IP 'Gambit,' Justices Told

    Sanofi and Regeneron on Monday urged the U.S. Supreme Court to turn away Amgen's petition regarding when antibody-based patents are enabled, saying Amgen's bid to overly expand its patent rights over a certain class of cholesterol drugs was a rightfully rejected "gambit."

  4. January 03, 2022

    Patent Cases To Watch In 2022

    The U.S. Supreme Court may consider whether a car part is a law of nature that can't be patented, and multiple courts are mulling the extent of the Patent Trial and Appeal Board's discretionary powers. Here's what you need to know about these and other high-profile patent cases.

  5. December 22, 2021

    Justices Told To Undo 'Impossible' Patent Enablement Rules

    GlaxoSmithKline and a group of law professors urged the U.S. Supreme Court on Wednesday to throw out a Federal Circuit decision invalidating two Amgen cholesterol drug patents, saying it set patent validity rules that are "impossible" for many life sciences patents to meet.

  6. November 23, 2021

    Amgen Takes Antibody Patents Invalidation To Supreme Court

    Amgen Inc. has asked the U.S. Supreme Court to overrule the Federal Circuit's invalidation of two patents covering its cholesterol medication Repatha, saying the circuit court's ruling "invades" the role of a jury and misunderstands enablement standards.